Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.
Saved in:
| Title: | Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma. |
|---|---|
| Authors: | Grover P; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Fiona Stanley Hospital, Perth, Australia; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, Australia., Lo SN; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Li I; Melanoma Institute Australia, The University of Sydney, Sydney, Australia., Kuijpers AMJ; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Kreidieh F; Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Williamson A; The Christie NHS Foundation Trust, Manchester, UK., Amaral T; Center for Dermato-oncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany., Dimitriou F; Department of Dermatology, Faculty of Medicine, University Hospital of Zurich, Zurich, Switzerland., Placzke J; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Olino K; Yale University School of Medicine, Smilow Cancer Center, New Haven Hospital, New Haven, USA., Vitale MG; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori-IRCCS Fondazione 'G. Pascale', Naples, Italy., Saiag P; University Department of Dermatology, Université de Versailles-Saint Quentin en Yvelines, APHP, Boulogne, France., Gutzmer R; Department of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum, Minden, Germany., Allayous C; AP-HP Dermato-oncology, Cancer Institute APHP Nord Paris Cité, Saint Louis Hospital, Paris, France., Olofsson Bagge R; Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg., Mattsson J; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden., Asher N; The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel HaShomer, Israel., Carter TJ; Mount Vernon Cancer Centre, Northwood, UK., Meniawy TM; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, Australia., Lawless AR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Czapla JA; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Warburton L; Department of Medical Oncology, Fiona Stanley Hospital, Perth, Australia; School of Medical and Health Sciences, Edith Cowan University, Joondalup, Perth, Australia., Gaudy-Marqueste C; Aix-Marseille Univ, APHM, Hôpital Timone, Service de dermatologie et de cancérologie cutanée, Marseille, France., Grob JJ; Aix-Marseille Univ, APHM, Hôpital Timone, Service de dermatologie et de cancérologie cutanée, Marseille, France., Collins RG; Vanderbilt University School of Medicine, Nashville, USA., Zhang E; Department of Surgery, Westmead Hospital, Sydney, Australia., Kessels JI; Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Neyns B; Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium., Mehmi I; Cedars-Sinai The Angeles Clinic and Research Institute, Los Angeles, USA., Hamid O; Cedars-Sinai The Angeles Clinic and Research Institute, Los Angeles, USA., Julve M; Renal, Skin and Cell Therapy Unit, The Royal Marsden NHS Foundation Trust, London, UK., Furness AJS; Renal, Skin and Cell Therapy Unit, The Royal Marsden NHS Foundation Trust, London, UK., Margolin KA; Department of Medical Oncology, Providence St. John's Cancer Institute, Santa Monica., Lev-Ari S; Georgetown Lombardi Comprehensive Cancer Center, Washington, USA., Ressler JM; Department of Dermatology, Medical University of Vienna, Vienna, Austria., Haque W; Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA., Khattak MA; Department of Medical Oncology, Fiona Stanley Hospital, Perth, Australia., Wicky A; Oncology, Lausanne University Hospital, Lausanne, Switzerland., Roberts-Thomson R; Medical Oncology Department, The Queen Elizabeth Hospital, Adelaide, Australia., Arance A; Hospital Clínic Barcelona and IDIBAPS, Barcelona, Spain., Warrier G; The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins, Baltimore, USA; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA., Schollenberger MD; The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins, Baltimore, USA; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA., Parente P; Eastern Health Clinical School, Box Hill Hospital, Monash University, Melbourne, Australia., Chatziioannou E; Center for Dermato-oncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany., Lipson EJ; The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins, Baltimore, USA; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University SOM, Baltimore, USA., Michielin O; Department of Oncology, Geneva University Hospital, Geneva, Switzerland., Weber JS; Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA., Hoeller C; Department of Dermatology, Medical University of Vienna, Vienna, Austria., Larkin J; Renal, Skin and Cell Therapy Unit, The Royal Marsden NHS Foundation Trust, London, UK., Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, USA., Essner R; Department of Surgery, Saint John's Cancer Institute at Providence St. John's Health Center, Santa Monica, USA., Johnson DB; Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, USA., Sullivan RJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA., Nathan P; Mount Vernon Cancer Centre, Northwood, UK., Schachter J; Sheba Medical Center-Tel HaShomer, Ramat Gan, Israel., Lebbe C; Université Paris Cite, APHP Dermato-oncology, Cancer Institute APHP Nord Paris Cité, INSERM U976, Saint Louis Hospital, Paris, France., Ascierto PA; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori-IRCCS Fondazione 'G. Pascale', Naples, Italy., Kluger H; Yale University School of Medicine, Smilow Cancer Center, New Haven Hospital, New Haven, USA., Rutkowski P; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Dummer R; Department of Dermatology, Faculty of Medicine, University Hospital of Zurich, Zurich, Switzerland., Garbe C; Center for Dermato-oncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany., Lorigan PC; The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK., Burton E; Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Tawbi HA; Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA., Haanen J; Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Carlino MS; Westmead and Blacktown Hospitals, University of Sydney, Melanoma Institute Australia, Sydney, Australia., Menzies AM; Melanoma Institute Australia, University of Sydney, Mater and Royal North Shore Hospitals, Australia., Long GV; Melanoma Institute Australia, University of Sydney, Mater and Royal North Shore Hospitals, Australia. Electronic address: Georgina.long@sydney.edu.au. |
| Source: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2025 Jul; Vol. 36 (7), pp. 807-818. Date of Electronic Publication: 2025 Apr 08. |
| Publication Type: | Journal Article; Multicenter Study |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
